What Can a Cosmeceutical Label Legally Say?

The word "cosmeceutical" has no legal meaning. The Federal Food, Drug, and Cosmetic Act (FD&C Act) recognizes cosmetics and drugs, and products that are both, but FDA states plainly that the law "does not recognize any such category as 'cosmeceuticals.'" What decides a product's legal status is not its ingredient list and not the word printed on the jar; it is the product's intended use. The moment a label claims a product changes the structure or a function of the body, or treats a disease, it has made a drug claim, and the evidence and approval that product must meet change with it.

Two legal categories, not three

Under the FD&C Act, a cosmetic is an article intended to cleanse, beautify, promote attractiveness, or alter the appearance without affecting the body's structure or functions. A drug is an article intended to diagnose, cure, mitigate, treat, or prevent disease, or intended to affect the structure or any function of the body. Those two definitions do the regulatory work. "Cosmeceutical" sits outside both. It is an industry marketing term for a cosmetic sold as having drug-like benefits, and FDA is explicit that using it on a label confers no special status and does not exempt the product from the requirements that apply to drugs.

A single product can be both at once. FDA's standing example is an antidandruff shampoo: it is a cosmetic because its intended use is to cleanse the hair, and it is also a drug because its intended use is to treat dandruff. Nothing about the bottle announces which rules apply. The claims do.

Intended use is what a claim signals

Intended use is the hinge, and FDA says it can be established in several ways: by claims on the labeling, in advertising, online, or in other promotional material, and even by consumer perception or by an ingredient widely known to have a particular effect. This is why two jars with nearly identical contents can land on opposite sides of the line based on wording alone.

The agency's own anti-aging guidance makes the boundary concrete. A product intended to make lines and wrinkles less noticeable simply by moisturizing the skin is a cosmetic. A product intended to remove wrinkles or to increase the skin's production of collagen is making a structure/function claim, which makes it a drug, or sometimes a device, even though the visible goal is cosmetic. "Hydrates for a smoother look" stays a cosmetic claim. "Boosts collagen synthesis" does not.

The same split runs through familiar ingredients. Over-the-counter retinol marketed to improve the look of skin is sold as a cosmetic; prescription tretinoin, marketed to treat acne or photoaging, is an approved drug. Sunscreen is a drug in the United States because preventing sunburn and reducing skin-cancer risk are disease and structure/function claims, which is why sunscreens are regulated under an over-the-counter drug framework rather than as cosmetics.

The evidence and approval tradeoff

Crossing the line is not a paperwork formality; it changes what a product must prove. Cosmetics do not require FDA premarket approval of the product itself. A product that makes a drug claim is a drug, and if it is not generally recognized by qualified experts as safe and effective for its labeled use, it is a "new drug" that cannot be legally marketed without an approved New Drug Application, or, for eligible categories, compliance with an over-the-counter monograph. That is the practical meaning of the boundary: a lawful drug claim invites a demand for adequate and well-controlled evidence of both safety and effectiveness, reviewed before marketing. A cosmetic claim does not.

That asymmetry cuts two ways for a reader. A drug claim, when it is lawful, stands behind a review standard that a cosmetic claim never has to meet. But many products carry drug-sounding language without ever having cleared that bar. FDA has issued warning letters to companies marketing cosmetics with anti-wrinkle or anti-aging claims that assert effects on the structure or function of the skin without drug approval. The claim does the persuading whether or not the evidence sits behind it.

Recent law is worth describing precisely, because it changed less than people assume. The Modernization of Cosmetics Regulation Act of 2022 added obligations for cosmetics, including facility registration, product listing, safety substantiation, and adverse-event reporting. It did not create a cosmeceutical category, and it did not impose premarket approval on cosmetics. The two-category structure, and the claim that moves a product between them, still governs.

Reading a label without being misled

A neutral way to read any "cosmeceutical" is to separate the appearance claim from the biological claim. Language about how skin looks or feels ("reduces the appearance of," "hydrates," "smooths") is cosmetic and carries no premarket evidence requirement. Language about what the product does inside the skin ("stimulates collagen," "repairs," "regenerates," "treats") is a drug claim, and the honest question becomes whether the product is an approved or monograph-compliant drug, or an unapproved one wearing a cosmetic label. A trial showing a measurable biological effect, if one exists, establishes what happened in a studied population under study conditions. It is not the same thing as marketing copy, and it is not the same thing as FDA approval of the claim.

This article is educational and is not medical advice; decisions about any specific product or skin condition belong with a qualified clinician who knows your history.